fda semaglutide compounding news The End of Compounded Semaglutide: Why the FDA's Decision Matters for Patients and Pharmacies - Seattle Plastic Surgery New Novo Nordisk initiatives support

The FDA has approved certain medications (Victoza, Ozempic, Trulicity) for cardiovascular risk reduction in patients with established cardiovascular disease and type 2 diabetes, and Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease who have overweight or obesity

The weight loss benefits of microdosing GLP-1 Research suggests that many dont need the higher doses of GLP-1 medications to see meaningful results

doi: 10.1053/j.gastro.2009.09.004 127 WidenmaierSBKimSJYangGKDe Los ReyesTNianCAsadiAet al

Not for use in diagnostic procedures

It is priming your receptor systems, establishing tolerance, and laying the foundation for higher doses to work effectively without overwhelming your body

A prior study had shown that retatrutide and semaglutide reduced pancreatic tumor mass in mice, along with weight loss